Stock 1177 SINO BIOPHARMACEUTICAL LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Sino Biopharmaceutical Limited Stock

Equities

1177

KYG8167W1380

Pharmaceuticals

Market Closed - Hong Kong S.E.
Other stock markets
 04:08:28 2024-05-24 am EDT 		5-day change 1st Jan Change
2.87 HKD -2.05% Intraday chart for Sino Biopharmaceutical Limited -8.01% -17.29%
07:16am Sino Biopharmaceutical's Renal Cancer Combination Treatment Shows Promise in Phase III Trials MT
May. 23 Sino Biopharmaceutical Limited Announces Positive Results on Phase III Study of Benmelstobart Injection in Combination with Anlotinib Hydrochloride Capsules for First-Line Treatment of Advanced Renal Cell Carcinoma CI

Financials

Sales 2024 * 29.1B 4.02B 31.37B Sales 2025 * 32.3B 4.46B 34.83B Capitalization 49.83B 6.88B 53.72B
Net income 2024 * 2.73B 376M 2.94B Net income 2025 * 3.11B 429M 3.35B EV / Sales 2024 * 1.56 x
Net cash position 2024 * 4.36B 602M 4.71B Net cash position 2025 * 7.41B 1.02B 7.99B EV / Sales 2025 * 1.31 x
P/E ratio 2024 *
18.4 x
P/E ratio 2025 *
16.1 x
Employees 25,806
Yield 2024 *
2%
Yield 2025 *
2.32%
Free-Float 50.56%
More Fundamentals * Assessed data

Chart Sino Biopharmaceutical Limited

Dynamic Chart

Latest news about Sino Biopharmaceutical Limited

Sino Biopharmaceutical's Renal Cancer Combination Treatment Shows Promise in Phase III Trials MT
Sino Biopharmaceutical Limited Announces Positive Results on Phase III Study of Benmelstobart Injection in Combination with Anlotinib Hydrochloride Capsules for First-Line Treatment of Advanced Renal Cell Carcinoma CI
Sino Biopharmaceutical's Novel Lung Cancer Drug Approved in China; Shares Up 5% MT
Sino Biopharmaceutical Limited Receives Marketing Approval from National Medical Products Administration of China CI
Wall Street, Earnings, Federal Reserve Roil Asian Stock Markets MT
Sino Biopharmaceutical Limited Announces Approval for Marketing of Category 1 Unecritinib Fumarate Capsules CI
Sino Biopharm Completes Phase I Study of Hepatitis B Drug MT
Lull in Geopolitical Tensions Lifts Asian Stock Markets MT
Hong Kong shares jump on policy support; China slips RE
Hong Kong shares jump 1.5% on policy support; China slips RE
Sino Biopharmaceutical Reaches Primary Endpoint for Clinical Research of Myelofibrosis Drug MT
Sino Biopharmaceutical Limited Announces Category 1 Innovative Drug Rovadicitinib Obtained Positive Results in Key Clinical Research for Registration CI
Sino Biopharm EBT Buys Back HK$12 Million Worth of Shares MT
Sino Biopharmaceutical Presents Cancer Drug's Phase-II Clinical Trial Results at AACR 2024 MT
Sino Biopharmaceutical Trustee Repurchases Shares MT
More news

Analyst Recommendations on Sino Biopharmaceutical Limited

Nomura Adjusts Sino Biopharmaceutical’s Price Target to HK$6.16 From HK$6.63, Keeps at Buy MT
Sino Biopharmaceutical Gets 'A' ESG Rating from MSCI MT
Nomura Adjusts Sino Biopharmaceutical's Price Target to HK$6.63 From HK$7.43, Keeps at Buy MT
Nomura Adjusts Sinobiopharma's Price Target to HK$7.43 From HK$7.78, Keeps at Buy MT
UBS Adjusts Sino Biopharmaceutical's Price Target to HK$7.5 From HK$8, Keeps at Buy MT
More recommendations

Press releases Sino Biopharmaceutical Limited

Sino Biopharmaceutical : 2023 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT PU
Sino Biopharm (1177.HK) Announces 2023 Annual Results AQ
Sino Biopharmaceutical (1177.HK) Announces 2023 Interim Results AQ
Sino Biopharmaceutical : 2022 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT PU
Sino Biopharm (1177.HK) Announces 2022 Annual Results AQ
More press releases

News in other languages on Sino Biopharmaceutical Limited

Borse Cina : chiudono miste, in rialzo Hong Kong con decisione su tassi
Las acciones de Hong Kong terminan planas tras una sesión volátil -- Market Talk
MÄRKTE ASIEN/Fester - Hoffen auf Zinspause
MÄRKTE ASIEN/Überwiegend aufwärts - Singapurer Zentralbank hält still
La actualización de la Lista Nacional de Medicamentos Reembolsables de China cumple las expectativas -- Market Talk
More news

Quotes and Performance

1 day-2.05%
1 week-7.12%
Current month+6.30%
1 month+7.09%
3 months-9.18%
6 months-23.87%
Current year-17.29%
More quotes

Highs and lows

1 week
2.83
Extreme 2.83
3.18
1 month
2.66
Extreme 2.66
3.18
Current year
2.29
Extreme 2.29
3.49
1 year
2.29
Extreme 2.29
3.93
3 years
2.29
Extreme 2.29
9.69
5 years
2.29
Extreme 2.29
11.24
10 years
1.76
Extreme 1.763
11.24
More quotes

Managers and Directors - Sino Biopharmaceutical Limited

Managers TitleAgeSince
S Y Tse CEO
 Chief Executive Officer 29 19-10-22
Ping Tse FOU
 Founder 72 00-02-01
Chun Ling Li DFI
 Director of Finance/CFO 53 -
Members of the board TitleAgeSince
Ping Tse FOU
 Founder 72 00-02-01
Cheung Ling Cheng BRD
 Director/Board Member 60 04-12-31
Hsin Tse BRD
 Director/Board Member 54 95-07-31
More insiders

ETFs positioned on Sino Biopharmaceutical Limited

Name Weight AuM 1st Jan change Investor Rating
KRANESHARES MSCI ALL CHINA HEALTH CARE INDEX UCITS ETF - USD ETF KraneShares MSCI All China Health Care Index UCITS ETF - USD
2.40% 2 M€ -16.67% -
LONCAR CHINA BIOPHARMA ETF - DISTRIBUTING - USD ETF Loncar China BioPharma ETF - Distributing - USD
2.02% 4 M€ -27.92%
KRANESHARES MSCI CHINA ESG LEADERS UCITS ETF ACC - USD ETF KraneShares MSCI China ESG Leaders UCITS ETF Acc - USD
0.82% 3 M€ +4.49% -
More ETFs positioned on Sino Biopharmaceutical Limited

Quotes

Date Price Change Volume
24-05-24 2.87 -2.05% 60 281 130
24-05-23 2.93 -0.34% 53,097,920
24-05-22 2.94 -0.34% 43,632,430
24-05-21 2.95 -5.75% 75,055,270
24-05-20 3.13 +1.29% 35,183,890

Delayed Quote Hong Kong S.E., May 24, 2024 at 04:08 am EDT

More quotes

Company Profile

Sino Biopharmaceutical Limited specialises in the development, manufacture and marketing of biopharmaceutical products primarily for the treatment of cancer, ophthalmia, hepatitis, orthopedic diseases and respiratory disorders. Net sales break down by category of products as follows: - chemical medicine products and biopharmaceutical drugs (97.6%); - other (2.4%).
Sector
Pharmaceuticals
Calendar
2024-06-10 - Final dividend
Related indices
HONG KONG HANG SENG
More about the company

Income Statement Evolution

More financial data

Ratings for Sino Biopharmaceutical Limited

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
26
Last Close Price
2.717 CNY
Average target price
4.256 CNY
Spread / Average Target
+56.61%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
SINO BIOPHARMACEUTICAL LIMITED Stock Sino Biopharmaceutical Limited
-17.29% 6.88B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+38.69% 728B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+33.98% 603B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.49% 360B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.24% 332B
ABBVIE INC. Stock AbbVie Inc.
+2.12% 279B
ASTRAZENECA PLC Stock AstraZeneca PLC
+16.30% 244B
NOVARTIS AG Stock Novartis AG
+7.84% 207B
ROCHE HOLDING AG Stock Roche Holding AG
-5.32% 205B
PFIZER, INC. Stock Pfizer, Inc.
-0.35% 163B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 1177 Stock